Tuebingen

First Patients are Vaccinated in IMPRINT*, immatics’ Pivotal Phase III Trial With IMA901 in Patients With Renal Cell Carcinoma (RCC)

immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients

New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) - Study to Start in 2010

TUEBINGEN, Germany, June 15, 2011 - igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).

MORE..

TUEBINGEN, Germany, April 11, 2011 - immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

MORE..

Older News

TUEBINGEN, Germany, September 21, 2010 - immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round.

MORE..